Microrna-31 emerges as a predictive biomarker of pathological response and outcome in locally advanced rectal cancer

Biblos-e Archivo/Manakin Repository

Show simple item record

dc.contributor.author Caramés, Cristina
dc.contributor.author Cristobal, Ion
dc.contributor.author Moreno, Víctor
dc.contributor.author Marín, Juan P.
dc.contributor.author González-Alonso, Paula
dc.contributor.author Torrejón, Blanca
dc.contributor.author Minguez, Pablo
dc.contributor.author Leon, Ana
dc.contributor.author Martín, José I.
dc.contributor.author Hernández, Roberto
dc.contributor.author Pedregal, Manuel
dc.contributor.author Martín, María J.
dc.contributor.author Cortés, Delia
dc.contributor.author García-Olmo, Damian
dc.contributor.author Fernández, María J.
dc.contributor.author Rojo, Federico
dc.contributor.author García-Foncillas, Jesús
dc.contributor.other UAM. Departamento de Cirugía es_ES
dc.contributor.other UAM. Departamento de Medicina es_ES
dc.contributor.other Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD) es_ES
dc.date.accessioned 2017-04-05T17:17:49Z
dc.date.available 2017-04-05T17:17:49Z
dc.date.issued 2016-06-01
dc.identifier.citation International Journal of Molecular Sciences 17.6 (2016): 878 en_US
dc.identifier.issn 1661-6596 (print) es_ES
dc.identifier.issn 1422-0067 (online) es_ES
dc.identifier.uri http://hdl.handle.net/10486/677921
dc.description.abstract Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision has emerged as the standard treatment for locally advanced rectal cancer (LARC) patients. However, many cases do not respond to neoadjuvant CRT, suffering unnecessary toxicities and surgery delays. Thus, identification of predictive biomarkers for neoadjuvant CRT is a current clinical need. In the present study, microRNA-31 expression was measured in formalin-fixed paraffin-embedded (FFPE) biopsies from 78 patients diagnosed with LARC who were treated with neoadjuvant CRT. Then, the obtained results were correlated with clinical and pathological characteristics and outcome. High microRNA-31 (miR-31) levels were found overexpressed in 34.2% of cases. Its overexpression significantly predicted poor pathological response (p = 0.018) and worse overall survival (OS) (p = 0.008). The odds ratio for no pathological response among patients with miR-31 overexpression was 0.18 (Confidence Interval = 0.06 to 0.57, p = 0.003). Multivariate analysis corroborated the clinical impact of miR-31 in determining pathological response to neoadjuvant CRT as well as OS. Altogether, miR-31 quantification emerges as a novel valuable clinical tool to predict both pathological response and outcome in LARC patients. en_US
dc.description.sponsorship This work was supported by PT13/0010/0012, PI13/02609 and PI15/00934 grants from “Instituto de Salud Carlos III FEDER, Madrid (Spain)” en_US
dc.format.extent 11 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en
dc.publisher MDPI AG en_US
dc.relation.ispartof International Journal of Molecular Sciences en_US
dc.rights © 2016 by the authors es_ES
dc.subject.other MiR-31 en_US
dc.subject.other Neoadjuvant chemoradiotherapy en_US
dc.subject.other Prognosis en_US
dc.subject.other Rectal cancer en_US
dc.title Microrna-31 emerges as a predictive biomarker of pathological response and outcome in locally advanced rectal cancer en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.relation.publisherversion http://dx.doi.org/10.3390/ijms17060878 es_ES
dc.identifier.doi 10.3390/ijms17060878 es_ES
dc.identifier.publicationfirstpage 878-1 es_ES
dc.identifier.publicationissue 6 es_ES
dc.identifier.publicationlastpage 878-12 es_ES
dc.identifier.publicationvolume 17 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en
dc.rights.cc Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Hernández Marco, Roberto (262106)

Files in this item


This item appears in the following Collection(s)

Show simple item record